SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

A. PROPOSED CONVERSION OF LOAN FROM CATERINE LIMITED INTO NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY ("SHARES"); AND

B. PROPOSED PLACEMENT OF AN AGGREGATE OF 19,748,000 NEW SHARES AT A PLACEMENT PRICE OF S$0.035 PER SHARE TO CERTAIN SUBSCRIBERS

(COLLECTIVELY, THE "PROPOSED TRANSACTIONS")

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcements (as defined below).

OVERVIEW

The Board of Directors (the "**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**", together with its subsidiaries, collectively, the "**Group**") wishes to announce that it intends to undertake the following Proposed Transactions:

(i) the proposed conversion of the Loan (as defined below) from Caterine Limited into new ordinary shares in the capital of the Company ("**Shares**"); and
(ii) the proposed placement of an aggregate of 19,748,000 new Shares at a placement price of S$0.035 per Share to certain subscribers.

Assuming the completion of the Proposed Transactions, the Company will allot and issue an aggregate of 169,474,000 new Shares, and the total number of Shares in the Company will increase from 1,062,020,642 Shares (as at the date of this announcement) ("**Existing Share Capital**") to 1,231,494,642 Shares ("**Enlarged Share Capital**").

Rationale for the Proposed Transactions

Based on the Group's latest announced unaudited consolidated financial statements for the financial year ended 30 June 2025 ("**FY2025**"), the Group has recorded a loss after tax and total comprehensive loss for the year amounting to approximately S$26.16 million, negative cash flow from operations of S$9.82 million and a net current liability position of S$11.77 million.

The Directors are of the view that the Proposed Transactions are beneficial for the Group as it will enable the Group to (i) strengthen the Group's financial position and net tangible assets value, (ii) improve the Group's cash flow to meet anticipated general working capital requirements (including meeting general overheads, financing requirements and other operating expenses), (iii) increase resources and working capital available to the Group to pursue new business opportunities as and when they arise, as part of the management's strategy for long-term business growth, (iv) reduce its indebtedness, gearing and loss per share, (v) with regard to the Caterine Debt Conversion (as defined below), eliminate the need for any cash repayment for the Outstanding Amount (as defined below) in view of the current financial obligations and cash position of the Group, and (iv) allow the Group to focus its resources on stabilising its business activities and improve its financial position.

A. PROPOSED CONVERSION OF LOANS FROM CATERINE LIMITED INTO NEW SHARES

1. Introduction

The Board refers to the Company's announcements dated 20 December 2024 and 26 February 2025 (the "**Announcements**") in relation to the Company's entry into a loan agreement dated 20 December

2024 with Caterine Limited (the "**Lender**"), pursuant to which the Lender granted a loan of a principal amount of S$5,000,000 ("**Loan**") to the Company and an extension of the Loan's maturity date to 13 December 2025, respectively.

The Board wishes to announce that the Company has on 30 September 2025 entered into a conditional debt conversion deed ("**Debt Conversion Deed**") with the Lender.

2. Caterine Debt Conversion

As at the date of the Debt Conversion Deed, the aggregate outstanding sum owing by the Company to the Lender is S$5,240,418 ("**Outstanding Amount**"), being the Loan and all interest accrued thereon as at 31 August 2025 (please refer to paragraph A(4.3) for waiver of interest from 1 September 2025). The maturity date of the Loan is 13 December 2025, and interest accrues on the aggregate outstanding indebtedness at the rate of 6.7% per annum.

Pursuant to the Debt Conversion Deed, the Lender has agreed to the repayment of the Outstanding Amount by way of conversion into 149,726,000 new ordinary shares in the capital of the Company (the "**Debt Conversion Shares**") at the issue price of S$0.035 per Debt Conversion Share ("**Issue Price**") (the "**Caterine Debt Conversion**"). The Debt Conversion Shares will be issued in full and final repayment and discharge of the Outstanding Amount owing by the Company to the Lender and accordingly, the Loan will be extinguished following the completion of the Caterine Debt Conversion.

Accordingly, following the completion of the Caterine Debt Conversion, the Company will have discharged its repayment obligations in relation to the Loan, and there will be no further amounts owing by the Company to the Lender.

3. Information on the Lender

Shareholders should note that the information relating to the Lender in this paragraph and elsewhere in this announcement and the Announcements was provided by the Lender. The Company and the Directors have not independently verified the accuracy and correctness of such information.

The Lender is a company incorporated in the British Virgin Islands, and is principally engaged in investment holdings. The Lender is a wholly-owned subsidiary of Casi Management Sdn. Bhd., which is in turn a company incorporated in Malaysia and is principally engaged in investment holding. To the best of knowledge of the Directors, the ultimate beneficial owner of Casi Management Sdn. Bhd. is Tan Sri Dato' Surin Upatkoon. The Lender was introduced to the Group through its business contacts and connections.

As at the date of this announcement, the Lender and its ultimate beneficial owner do not hold, whether directly or indirectly, any Shares in the Company. To the best of knowledge of the Directors, save as stated in the above paragraph, the Lender and its ultimate beneficial owners does not have any connection (including business relationship) with the Group, the Company, its Directors and substantial shareholders, and is not a person to whom the Company is prohibited from issuing shares to, as provided by Rule 812(1) of the Listing Manual Section B: Rules of Catalist of Singapore Exchange Securities Trading Limited ("**SGX-ST**") ("**Catalist Rules**").

4. Terms of the Caterine Debt Conversion

4.1 Debt Conversion Shares and Price

The Issue Price represents a discount of approximately 8.85% to the weighted average price of S$0.0384 for each Share, for trades done on 29 September 2025, being the market day on which the trading halt was called by the Company. For avoidance of doubt, there were no trades of the Shares on the preceding market day.

The Debt Conversion Shares represent approximately 14.10% of the Existing Share Capital and approximately 12.16% of the Enlarged Share Capital. Assuming only the completion of the Caterine Debt Conversion, as Tan Sri Dato' Seri Vincent Tan Chee Yioun remains a controlling shareholder of the

Company, the Caterine Debt Conversion will not result in a transfer of controlling interest under Rule 803 of the Catalist Rules.

The Debt Conversion Shares will, when allotted and issued, be credited as fully-paid Shares free from any and all encumbrances and rank *pari passu* in all respects with and carry all rights similar to the existing issued Shares, except that they will not rank for any dividend, right, allotment or other distributions the record date for which falls on or before the date of issue of the Debt Conversion Shares.

The Debt Conversion Shares are intended to be issued pursuant to the general share issuance mandate (the "**General Mandate**") obtained at the annual general meeting of the Company held on 27 December 2024 ("**2024 AGM**") which, pursuant to Section 161 of the Companies Act 1967 of Singapore ("**Companies Act**") and Rule 806 of the Catalist Rules, authorises the Directors to allot and issue new Shares not exceeding 100% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) at the time the General Mandate was passed, of which the aggregate number of Shares to be issued other than on a *pro rata* basis to the shareholders of the Company shall not exceed 50% of the total number of issued Shares (excluding treasury shares and subsidiary holdings).

The number of issued Shares (excluding treasury shares and subsidiary holdings) as at the 2024 AGM was 1,048,099,074 Shares. Accordingly, the maximum number of Shares that may be issued pursuant to the General Mandate other than on a *pro rata* basis is 524,049,537 Shares.

Under the General Mandate, the Company had (i) on 11 February 2025 allotted and issued an aggregate of 3,921,568 new Shares and (ii) on 28 March 2025 allotted and issued an aggregate of 10,000,000 new Shares, pursuant to the vesting of awards to certain eligible participants under the Singapore Institute of Advanced Medicine Holdings Performance Share Plan. Further details are set out in the Company's announcements dated 11 February 2025 and 28 March 2025.

As such, the maximum number of remaining Shares that may be issued pursuant to the General Mandate other than on a *pro rata* basis shall not exceed 510,127,969 Shares as at the date of this announcement. Accordingly, the allotment and issue of all the Debt Conversion Shares pursuant to the Caterine Debt Conversion and Placement Shares fall within the limits of the General Mandate.

The Company will, through its sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), make an application to the SGX-ST for the listing of and quotation for the Debt Conversion Shares on the Catalist Board of the SGX-ST (the "**Catalist**"). An announcement will be made in due course to notify the Shareholders when the listing and quotation notice ("**LQN**") is obtained.

4.2 Conditions Precedent

The completion of the Caterine Debt Conversion is conditional upon the fulfilment of the following conditions precedent, *inter alia*:

(i) the LQN being obtained from the SGX-ST for the listing of and quotation for the Debt Conversion Shares on Catalist and not having been revoked or amended, and any conditions in relation thereto being fulfilled;

(ii) the allotment and issue of the Debt Conversion Shares being in compliance with the Securities and Futures Act 2001 of Singapore ("**SFA**") in connection with offers of securities and not being prohibited by any statute, order, rule or regulation in Singapore; and

(iii) the exemption under Sections 274 and/or 275 of the SFA being applicable to the subscription for and the allotment and issue of the Debt Conversion Shares under this Deed.

If any of the conditions set out in the Debt Conversion Deed is not satisfied (or waived by the Company) on or before the long-stop date of 31 December 2025 (or such other date as the parties may agree in

writing), the Company will have the right to terminate the Debt Conversion Deed.

4.3 Further agreements and undertakings of the Lender

Under the Debt Conversion Deed, the Lender has agreed that the maturity date of the Loan will be extended to the date of completion of the Caterine Debt Conversion, and further agreed and undertook not to demand repayment of the Loan on or prior to such completion. The Lender has also agreed that no further interest will accrue on the Loan and the Outstanding Amount from 1 September 2025 up to such date of completion.

5. Shareholding Interests of the Lender

The Lender's existing shareholding interest and shareholding interests in the Company upon (i) the Caterine Debt Conversion and (ii) the Proposed Transactions are as follows:

Lender	Shareholding Interest		
	Existing [(1)] (%)	After Caterine Debt Conversion [(2)] (%)	After Proposed Transactions [(3)] (%)
Caterine Limited	-	12.36	12.16

Notes:

(1) Based on the Existing Share Capital of 1,062,020,642 Shares as at the date of this announcement (adjusted for rounding).

(2) Based on the total enlarged number of Shares of 1,211,746,642 Shares (adjusted for rounding), assuming the completion of the Caterine Debt Conversion.

(3) Based on the Enlarged Share Capital of 1,231,494,642 Shares (adjusted for rounding), assuming the completion of the Proposed Transactions.

B. PROPOSED PLACEMENT OF AN AGGREGATE OF 19,748,000 NEW SHARES AT A PLACEMENT PRICE OF S$0.035 PER SHARE TO CERTAIN SUBSCRIBERS

1. Introduction

The Board wishes to announce that the Company has on 30 September 2025 entered into subscription agreements ("**Subscription Agreements**") with the three following entities (the "**Subscribers**") respectively in relation to the allotment and issue of an aggregate of 19,748,000 new Shares ("**Placement Shares**") at an issue price of S$0.035 per Placement Share ("**Placement Price**") to each Subscriber or such persons nominated by each Subscriber (which includes the Subscribers' associated companies or funds managed by them) ("**Nominees**"), on the terms and conditions of the respective Subscription Agreements ("**Proposed Placement**"):

(i) subscription agreement with PHEIM Asset Management (Asia) Pte Ltd ("**PHEIM SG**") ("**PSG Agreement**"), in relation to the allotment and issue of an aggregate of 6,213,000 Placement Shares at the Placement Price, amounting to an aggregate consideration of S$217,500;

(ii) subscription agreement with PHEIM Asset Management Sdn. Bhd. ("**PHEIM MY**") ("**PMY Agreement**"), in relation to the allotment and issue of an aggregate of 13,248,000 Placement Shares at the Placement Price, amounting to an aggregate consideration of S$463,800; and

(iii) subscription agreement with PHEIM Islamic Asset Management Sdn. Bhd. ("**PHEIM IAM**") ("**PIAM Agreement**"), in relation to the allotment and issue of an aggregate of 287,000 Placement Shares at the Placement Price, amounting to an aggregate consideration of S$10,100.

Each Subscriber has agreed to subscribe for the Placement Shares under the respective Subscription Agreements, and nominated the following Nominees for the Placement Shares specified below:

S/N	Nominee	Placement Consideration (S$)	Number of Placement Shares	Number of Placement Shares as a percentage of the Existing Share Capital [(1)] (%)	Number of Placement Shares as a percentage of the Enlarged Share Capital [(2)] (%)
PSG Agreement					
1.	PHEIM ASEAN All-Cap Equity Fund	146,500	4,185,000	0.39	0.34
2.	PHEIM VCC – PHEIM Emerging Asia Ex-Japan Balanced Fund	71,000	2,028,000	0.19	0.16
Sub-Total (PHEIM SG):		**217,500**	**6,213,000**	**0.59** [(3)]	**0.50**
PMY Agreement					
3.	Thong Thye Chiang Sdn Bhd	16,000	457,000	0.04	0.04
4.	Thong Thye Chiang Realty Sdn Bhd	7,100	202,000	0.02	0.02
5.	PHEIM Emerging Companies Balanced Fund	25,000	714,000	0.07	0.06
6.	Dana Makmur PHEIM	307,000	8,771,000	0.83	0.71
7.	Benta Wawasan Sdn Bhd	36,000	1,028,000	0.10	0.08
8.	German-Malaysian Institute	26,400	754,000	0.07	0.06
9.	PHEIM Asia Ex-Japan Fund	11,200	320,000	0.03	0.03
10.	PHEIM Asia Ex-Japan Islamic Fund	24,700	705,000	0.07	0.06
11.	Saham Sabah Bhd	10,400	297,000	0.03	0.02
Sub-Total (PHEIM MY):		**463,800**	**13,051,000**	**1.33**	**1.14**
PIAM Agreement					
12.	PHEIM Global ESG Islamic Fund	6,400	182,000	0.02	0.01

S/N	Nominee	Placement Consideration (S$)	Number of Placement Shares	Number of Placement Shares as a percentage of the Existing Share Capital [(1)] (%)	Number of Placement Shares as a percentage of the Enlarged Share Capital [(2)] (%)
13.	PHEIM Asean Islamic Fund	3,700	105,000	0.01	0.01
Sub-Total (PHEIM IAM):		**10,100**	**287,000**	**0.03**	**0.02**
TOTAL:		**691,400**	**19,748,000**	**1.86 [(3)]**	**1.60**

Notes:

(1) Based on the number of Placement Shares divided by the Existing Share Capital of 1,062,020,642 Shares as at the date of this announcement (adjusted for rounding).

(2) Based on the number of Placement Shares divided by the Enlarged Share Capital of 1,231,494,642 Shares (adjusted for rounding), assuming the completion of the Proposed Transactions.

(3) Any discrepancy between the sum of the figures stated and the total thereof is due to rounding.

2. The Proposed Placement

2.1 Placement Shares and Price

The Placement Price represents a discount of approximately 8.85% to the weighted average price of S$0.0384 for each Share, for trades done on 29 September 2025, being the market day which the trading halt was called by the Company. For avoidance of doubt, there were no trades of the Shares on the preceding market day.

The Placement Shares represent approximately 1.86% of the Existing Share Capital and approximately 1.60% of the Enlarged Share Capital.

The Placement Shares are intended to be issued pursuant to the General Mandate obtained at 2024 AGM. As the maximum number of remaining Shares that may be issued pursuant to the General Mandate other than on a *pro rata* basis shall not exceed 510,127,969 Shares as at the date of this announcement, the allotment and issue of all the Placement Shares pursuant to the Proposed Placement falls within the limits of the General Mandate. Please refer to paragraph A(4.1) of this announcement for further details relating to the General Mandate.

The Placement Shares, when issued and fully paid, shall be issued unencumbered and free from any security interests, charges, claims (including pre-emptive rights) or liens and will be freely transferable, and shall rank *pari passu* with and shall carry all rights similar to the existing Shares except that they will not rank for any dividend, right, allotment or other distributions, the record date for which falls on or before the date of completion of the Proposed Placement.

2.2 Conditions Precedent

The completion of each Subscription Agreement is conditional upon, *inter alia*:

(i) the LQN for the listing of and quotation for the Placement Shares on Catalist being obtained from the SGX-ST, and such approval not being revoked, rescinded or cancelled prior to such completion; and

(ii) the exemption under Sections 274 and/or 275 of the SFA being applicable to the subscription for and the allotment and issue of the Placement Shares under the Subscription Agreement.

Under each Subscription Agreement, if any of the conditions set out therein is not fulfilled upon the expiry of three (3) months from the date of the Subscription Agreement, the Subscription Agreement shall become null and void. Upon such event, all monies paid by the Subscribers and/or the Nominees (as the case may be) (if any) shall be refunded to the Subscribers and/or the Nominees (as the case may be) forthwith free of interest, and neither the Subscribers nor the Company will have any right to claim against the other under the Subscription Agreement for whatsoever reason.

There will not be any prospectus or offer information statement issued in connection with the Proposed Placement as the Proposed Placement will be made pursuant to exemptions under Sections 274 and/or 275 of the SFA. No placement agent has been appointed in respect of the Proposed Placement. No commission or referral fees pursuant to the Proposed Placement will be paid to any party.

2.3 Completion

The Sponsor will be submitting an application on behalf of the Company to the SGX-ST for the listing of and quotation for the Placement Shares on the Catalist. The Company will make the necessary announcements once the LQN for the listing of and quotation for the Placement Shares is obtained from the SGX-ST.

The Subscribers shall pay the Placement Consideration to the Company within two (2) business days from the Company's receipt of the LQN or (if applicable) Shareholders' approval in a general meeting for the allotment and issue of the Placement Shares at the Placement Price, whichever is later.

The completion of the Proposed Placement will occur within three (3) business days after the Company's receipt of the respective portion of Placement Consideration from the Subscribers.

3. Information on the Subscribers and Nominees

Shareholders should note that the information relating to the Subscribers and Nominees in this paragraph and elsewhere in this announcement was provided by the respective Subscribers. The Company and the Directors have not independently verified the accuracy and correctness of such information.

The background details of the Subscribers and Nominees are as follows:

S/N	Subscriber / Nominee	Background
(A)	**PHEIM SG**	PHEIM SG is a company incorporated in Singapore, and is principally engaged in the provision of investment management and advisory services. PHEIM SG holds a Capital Markets Services Licence regulated by the Monetary Authority of Singapore. The Nominees of PHEIM SG under the PSG Agreement are funds managed by PHEIM SG. The major shareholder of PHEIM SG, Dr Tan Chong Koay, is also the major shareholder of PHEIM MY and PHEIM IAM. PHEIM SG, PHEIM MY and PHEIM IAM operate independently. PHEIM SG is not a holding company or subsidiary of the other Subscribers. PHEIM IAM is a wholly-owned subsidiary of PHEIM MY.
1.	PHEIM ASEAN All-Cap Equity Fund	PHEIM ASEAN All-Cap Equity Fund is an exempted company incorporated with limited liability under the laws of the Cayman Islands. The fund is currently managed by PHEIM SG.
2.	PHEIM VCC – PHEIM Emerging Asia Ex-Japan Balanced Fund	PHEIM VCC – PHEIM Emerging Asia Ex-Japan Balanced Fund is a sub-fund of Pheim VCC, a company incorporated as an umbrella Variable Capital Company with segregated sub-funds under the laws of

S/N	Subscriber / Nominee	Background
		Singapore. The fund is currently managed by PHEIM SG.
(B)	**PHEIM MY**	PHEIM MY is a company incorporated in Malaysia, and is an asset management company licensed under the Capital Markets and Services Act 2007 of Malaysia. The Nominees of PHEIM MY under the PMY Agreement are funds managed by PHEIM MY. The major shareholder of PHEIM MY, Dr Tan Chong Koay, is also the major shareholder of PHEIM SG and PHEIM IAM. PHEIM SG, PHEIM MY and PHEIM IAM operate independently. PHEIM IAM is a wholly-owned subsidiary of PHEIM MY.
3.	Thong Thye Chiang Sdn Bhd	Thong Thye Chiang Sdn Bhd is a limited liability company incorporated in Malaysia, and is principally engaged in investment holdings and the provision of management services to its subsidiary. The fund is currently managed by PHEIM MY. Thong Thye Chiang Sdn Bhd is the parent company of another Nominee, Thong Thye Chiang Realty Sdn Bhd.
4.	Thong Thye Chiang Realty Sdn Bhd	Thong Thye Chiang Realty Sdn Bhd is a limited liability company incorporated in Malaysia, and is principally engaged in investment holdings and the provision of management services to its subsidiary. The fund is currently managed by PHEIM MY. Thong Thye Chiang Realty Sdn Bhd is a subsidiary of another Nominee, Thong Thye Chiang Sdn Bhd.
5.	PHEIM Emerging Companies Balanced Fund	PHEIM Emerging Companies Balanced Fund is a unit trust fund distributed by PHEIM Unit Trusts Bhd (PUTB), a Unit Trust Management Company (UTMC) incorporated in Malaysia and licensed under the Securities Commission Malaysia. The fund is currently managed by PHEIM MY.
6.	Dana Makmur PHEIM	Dana Makmur Pheim is a unit trust fund distributed by PHEIM Unit Trusts Bhd (PUTB), a Unit Trust Management Company (UTMC) incorporated in Malaysia and licensed under the Securities Commission Malaysia. The fund is currently managed by PHEIM MY.
7.	Benta Wawasan Sdn Bhd	Benta Wawasan Sdn Bhd, is a limited liability company incorporated in Malaysia, and is principally engaged in the development of tree plantations and oil palm plantations and the operation of crude palm oil mill. The fund is currently managed by PHEIM MY.
8.	German-Malaysian Institute	German-Malaysian Institute was incorporated in Malaysia, and is principally engaged in the Education business. The fund is currently managed by PHEIM MY.
9.	PHEIM Asia Ex-Japan Fund	PHEIM Asia Ex-Japan Fund is a unit trust fund distributed by PHEIM Unit Trusts Bhd (PUTB), a Unit Trust Management Company (UTMC) incorporated in Malaysia and licensed under the Securities Commission Malaysia. The fund is currently managed by PHEIM MY.

S/N	Subscriber / Nominee	Background
10.	PHEIM Asia Ex-Japan Islamic Fund	PHEIM Asia Ex-Japan Islamic Fund is a unit trust fund distributed by PHEIM Unit Trusts Bhd (PUTB), a Unit Trust Management Company (UTMC) incorporated in Malaysia and licensed under the Securities Commission Malaysia. The fund is currently managed by PHEIM MY.
11.	Saham Sabah Bhd	S Saham Sabah Bhd, is a limited company incorporated in Malaysia, and is principally engaged in the management and administration of unit trust funds. The fund is currently managed by PHEIM MY.
(C)	**PHEIM IAM**	PHEIM IAM is a company incorporated in Malaysia, and is an islamic asset management company licensed under the Capital Markets and Services Act 2007 of Malaysia. The Nominees of PHEIM IAM under the PIAM Agreement are funds managed by PHEIM IAM. The major shareholder of PHEIM IAM, Dr Tan Chong Koay, is also the major shareholder of PHEIM SG and PHEIM MY. PHEIM SG, PHEIM MY and PHEIM IAM operate independently. PHEIM IAM is a wholly-owned subsidiary of PHEIM MY.
12.	PHEIM Global ESG Islamic Fund	PHEIM Global ESG Islamic Fund is a unit trust fund distributed by PHEIM Unit Trusts Bhd (PUTB), a Unit Trust Management Company (UTMC) incorporated in Malaysia and licensed under the Securities Commission Malaysia. The fund is currently managed by PHEIM IAM.
13.	PHEIM Asean Islamic Fund	PHEIM Asean Islamic Fund is a unit trust fund distributed by PHEIM Unit Trusts Bhd (PUTB), a Unit Trust Management Company (UTMC) incorporated in Malaysia and licensed under the Securities Commission Malaysia. The fund is currently managed by PHEIM IAM.

Save for the German-Malaysian Institute and PHEIM Global ESG Islamic Fund, the remaining Nominees are existing Shareholders with shareholding interests as follows:

S/N	Nominee	Shareholding Interest		
		Existing [(1)] (%)	**After the Proposed Placement [(2)] (%)**	**After the Proposed Transactions [(3)] (%)**
PSG Agreement				
1.	PHEIM ASEAN All-Cap Equity Fund	0.44	0.82	0.72
2.	PHEIM VCC – PHEIM Emerging Asia Ex-Japan Balanced Fund	0.23	0.42	0.37
PMY Agreement				
3.	Thong Thye Chiang Sdn Bhd	0.06	0.10	0.09
4.	Thong Thye Chiang Realty Sdn Bhd	0.04	0.06	0.05

S/N	Nominee	Shareholding Interest		
		Existing (1) (%)	After the Proposed Placement (2) (%)	After the Proposed Transactions (3) (%)
5.	PHEIM Emerging Companies Balanced Fund	0.09	0.16	0.14
6.	Dana Makmur PHEIM	1.31	2.10	1.85
7.	Benta Wawasan Sdn Bhd	0.11	0.21	0.18
8.	German-Malaysian Institute	-	0.07	0.06
9.	PHEIM Asia Ex-Japan Fund	0.04	0.07	0.06
10.	PHEIM Asia Ex-Japan Islamic Fund	0.11	0.18	0.16
11.	Saham Sabah Bhd	0.03	0.06	0.05
PIAM Agreement				
12.	PHEIM Global ESG Islamic Fund	-	0.02	0.01
13.	PHEIM Asean Islamic Fund	0.01	0.02	0.02

Notes:

(1) Based on the Existing Share Capital of 1,062,020,642 Shares as at the date of this announcement (adjusted for rounding).

(2) Based on the total enlarged number of issued and paid-up Shares of 1,081,768,642 Shares (adjusted for rounding), assuming the completion of the Proposed Placement.

(3) Based on the Enlarged Share Capital of 1,231,494,642 Shares (adjusted for rounding), assuming the completion of the Proposed Transactions.

The Subscribers were introduced to the Group through its business contacts and connections. As the Company understands, (i) the Subscribers have entered into the Subscription Agreements on behalf of the respective Nominees for financial investment purposes and (ii) the Nominees will not be holding their respective Placement Shares on trust on behalf of any undisclosed third party. The Company confirms that the Proposed Placement will not result in any material conflict of interest as there are no other relationships between the Subscribers, Nominees and the Company, save as set out above. The Subscribers' subscription of the Placement Shares is purely for investment purposes only, and the Subscribers and Nominees have no intention of influencing the management of, or exercising control over, the Company, and are not acting in concert with any Shareholder to obtain or consolidate control of the Company. PHEIM SG, PHEIM MY and PHEIM IAM, of which Dr Tan Chong Koay is the major shareholder, will collectively manage an aggregate of (i) approximately 4.27% shareholding interest in the Company after the completion of the Proposed Placement, and (ii) approximately 3.75% of the Enlarged Share Capital.

To the best of the Company's knowledge, save as disclosed above, the Subscribers and Nominees do not have any connection (including business relationships) with the Company, its Directors, substantial shareholders and ultimate beneficial owners.

The Placement Shares will not be issued to any of the persons listed in Rule 812(1) of the Catalist Rules. In addition, the issuance of the Placement Shares will not be made without the prior approval of the Shareholders in a general meeting if such issuance would bring about a transfer of controlling interest.

There is no moratorium imposed on the Placement Shares. No share borrowing arrangement has been entered into to facilitate the Proposed Placement.

4. Use of Proceeds

Assuming that the Proposed Placement is fully subscribed, the estimated net proceeds from the Proposed Placement (after deducting professional fees and related estimated expenses pertaining to the Proposed Placement of approximately S$47,000 to be borne by the Company) will be approximately S$644,400 (the "**Net Placement Proceeds**").

The Company intends to allocate the Net Placement Proceeds entirely to fund the general working capital (including meeting general overheads, financing requirements and other operating expenses) of the Group. In addition, ongoing renovation and maintenance of medical equipment might require additional working capital needs.

Pending the deployment of the Net Placement Proceeds, the Company intends to place the Net Placement Proceeds from the Proposed Placement with banks and/or financial institutions or use the Net Placement Proceeds for any other purposes on a short-term basis, as the Directors may deem fit in the best interests of the Group.

The Company will make periodic announcements on the utilisation of the Net Placement Proceeds as and when the funds are materially disbursed and whether such use is in accordance with the stated use and in accordance with the percentage allocated. The Company will also provide a status report on the use of the Net Placement Proceeds in the Company's interim and full year financial statements and the Company's annual report. Where the Net Placement Proceeds are used for working capital purposes, the Company will provide a breakdown with specific details on how the Net Placement Proceeds have been applied in the announcements and the annual report. Where there is any material deviation from the stated use of the Net Placement Proceeds, the Company will announce the reasons for such deviation.

C. FINANCIAL EFFECTS OF THE PROPOSED TRANSACTIONS

The tables illustrating the financial effects of the Proposed Transactions have been prepared based on the Group's latest unaudited consolidated financial statements for FY2025 and the following principal assumptions:

(i) the financial effects on the net tangible assets ("**NTA**") or net tangible liabilities per share of the Group are computed based on the assumption that the Proposed Transactions had been completed on 30 June 2025; and

(ii) the financial effect on the loss per Share ("**LPS**") of the Group is computed based on the assumption that the Proposed Transactions had been completed on 1 July 2024.

For the avoidance of doubt, the financial effects of the respective Proposed Transactions on the Group are for illustrative purposes only and are, therefore, not indicative of the actual financial performance or position of the Group after the completion of the Proposed Transactions. These financial effects do not take into account any issuance of new Shares, on or after 1 July 2025. The financial effects also do not take into account any fees and expenses to be incurred in relation to the respective Proposed

Transactions.

1. Share Capital

Assuming the completion of (a) the Caterine Debt Conversion, followed by (b) the Proposed Placement, the changes in the total number of Shares in the Company will be as follows:

Proposed Transaction	Total Number of Shares in the Company
As at date of this announcement	1,062,020,642
After the completion of the Caterine Debt Conversion	1,211,746,642
After the completion of the Proposed Placement	1,231,494,642

2. NTA per Share of the Group

Assuming that the Proposed Transactions had been completed on 30 June 2025, the financial effect on the NTA per share of the Group as at 30 June 2025 is as follows:

	Before the Caterine Debt Conversion	After the Caterine Debt Conversion	After the Proposed Placement
NTA attributable to equity holders of the Group (S$'000)	55,632	60,872	61,517
Number of Shares	1,062,020,642 (1)	1,211,746,642	1,231,494,642
NTA per share (S$ cents) (2)	5.24	5.02	5.00

Notes:

(1) Based on the total number of Shares of 1,062,020,642 Shares as at 30 June 2025 and the date of this announcement.

(2) NTA refers to net asset value of the Group less intangible assets and goodwill.

3. Loss per Share of the Group

Assuming the Proposed Transactions had been completed on 1 July 2024, the financial effect on the LPS of the Group for FY2025 is as follows:

	Before the Caterine Debt Conversion	After the Caterine Debt Conversion	After the Proposed Placement
Net loss attributable to equity holders of the Group (S$'000)	26,161	25,977 (2)	26,024 (2)
Number of Shares	1,062,020,642 (1)	1,211,746,642	1,231,494,642
LPS (S$ cents)	2.46	2.14	2.11

Notes:

(1) Based on the total number of Shares of 1,062,020,642 Shares as at 30 June 2025 and the date of this

announcement.

(2) For illustrative purposes, the Company has removed the interest pertaining to the Caterine Debt Conversion as at 1 July 2024.

D. CONFIRMATION BY DIRECTORS IN RESPECT OF THE PROPOSED TRANSACTIONS

(A) **Caterine Debt Conversion**: As the Company intends to settle and discharge its repayment obligations in relation to the Loan by way of the Caterine Debt Conversion, the Caterine Debt Conversion will not result in any new cash proceeds for the Company.

(B) **Proposed Placement**: The Directors are of the view that the Proposed Placement is beneficial for the Group for such reasons as set out in the "Overview" section and paragraph B(4) of this announcement.

The Directors are of the opinion that, after taking into consideration:

(i) the Group's present bank facilities, the working capital available to the Group is sufficient to meet its present requirements, and the reasons for the Proposed Transactions are set out in the rationale section of this announcement;

(ii) the Group's present bank facilities and the settlement of the Outstanding Amount in relation to the Loan, the working capital available to the Group is sufficient to meet its present requirements; and

(iii) the Group's present bank facilities and the Net Placement Proceeds arising from the Proposed Placement, the working capital available to the Group is sufficient to meet its present requirements.

E. INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS IN RESPECT OF THE PROPOSED TRANSACTIONS

(A) **Caterine Debt Conversion**: None of the Directors or substantial shareholders of the Company and their respective associates has any interest, direct or indirect, in the Caterine Debt Conversion, other than through their respective shareholdings (if any), employment and/or directorship (as applicable) in the Company.

(B) **Proposed Placement**: None of the Directors or substantial shareholders of the Company and their respective associates has any interest, direct or indirect, in the Proposed Placement, other than through their respective shareholdings (if any), employment and/or directorship (as applicable) in the Company.

F. DOCUMENTS FOR INSPECTION IN RESPECT OF THE PROPOSED TRANSACTIONS

(A) **Caterine Debt Conversion**: A copy of the Debt Conversion Deed is available for inspection; and

(B) **Proposed Placement**: Copies of the Subscription Agreements are available for inspection,

during normal office hours at the registered office of the Company at 1 Biopolis Drive, #02-01, Amnios, Singapore 138622 for a period of three (3) months from the date of this announcement.

G. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm after making all reasonable enquiries that, to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the Proposed Transactions, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading.

Where information in this announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to

ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in the announcement in its proper form and context.

H. CAUTIONARY STATEMENT

The Directors would like to advise the Shareholders and potential investors that the Proposed Transactions are respectively subject to certain conditions being fulfilled and there is no certainty or assurance as at the date of this announcement that the Proposed Transactions will materialise or will be completed or that no changes will be made to the respective terms thereof. Accordingly, Shareholders are advised to exercise caution when dealing or trading in the Shares. Shareholders and potential investors are advised to read this announcement and any further update announcement(s) released by the Company in connection with the Proposed Transactions carefully. Shareholders and potential investors who are in any doubt as to the action that they should take, should consult their stockbroker, bank manager, solicitor, financial, tax or other professional adviser immediately.

I. FURTHER ANNOUNCEMENTS

Following, and subject to, the completion of the Proposed Transactions, the Company is exploring a potential rights cum warrants exercise, as well as the potential conversion of loans from a subsidiary of the controlling shareholder into new Shares.

The Company will make further announcement(s) in relation to the Proposed Transactions and the abovementioned transactions, as and when required.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
30 September 2025

Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has been reviewed by the Sponsor. It has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.